Acadia Pharmaceuticals (ACAD) Operating Expenses (2010 - 2026)

Acadia Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $272.7 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 21.18% year-over-year to $272.7 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 33.22% increase from a year earlier, with the FY2025 full-year figure at $966.7 million, up 32.97% from the prior year.
• Operating Expenses grew to $272.7 million in Q1 2026 per ACAD's latest filing, from $266.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $272.7 million in Q1 2026 and bottomed at $106.1 million in Q4 2024.
• The 5-year median for Operating Expenses is $211.5 million (2024), against an average of $206.3 million.
• Across the five-year window, Operating Expenses sank 45.89% in 2024 and soared 151.27% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $182.6 million in 2022, then grew by 7.42% to $196.1 million in 2023, then sank by 45.89% to $106.1 million in 2024, then surged by 151.27% to $266.6 million in 2025, then advanced by 2.28% to $272.7 million in 2026.
• Per Business Quant, the three latest ACAD Operating Expenses figures stand at $272.7 million (Q1 2026), $266.6 million (Q4 2025), and $242.9 million (Q3 2025).